Mumps serological surveillance following 10 years of a one-dose mumps-containing-vaccine policy in Fujian Province, China

Figures & data

Table 1. Seroprevalence and GMCs of mumps antibody by age, gender, and number of vaccine doses received in Fujian Province, China, 2018.

Characteristic	Sample size（n=4,925）	Seroprevalence n, % (95% CI)	P value	GMC (95%CI) (IU/mL)	P value
Age
0–7 months	109	28,25.7% (17.4–33.0)	P<0.001	53.0(43.4–64.6)	P<0.001
8–9 months	90	6,6.7% (2.2–12.2)		25.5(21.8–29.9)
10–12 months	138	8,5.8.0% (2.2–10.1)		23.9(21.1–27.2)
13–17 months	116	4,3.4.0% (0.9–6.9)		22.8(20.2–25.6)
1.5-years	258	197,76.4% (71.9–81.4)		199.1(169.2–234.2)
2-years	330	301,91.2% (88.2–94.2)		361.4(327.3–399.1)
3-years	332	300,90.4% (87.3–93.4)		473.2(426.5–524.9)
4-years	334	318,95.2% (92.8–97.3)		515.2(472.9–561.4)
5-years	288	257,89.2% (85.4–92.7)		366.4(328.8–408.4)
6-years	134	120,89.6% (84.3–94.0)		291.7(251.4–338.6)
7-years	50	45,90.0% (80.0–98.00)		459.2(358.3–588.6)
8-years	65	58,89.2% (81.5–95.4)		359.7(291–444.8)
9-years	46	38,82.6% (69.57–93.48)		283.1(219.9–364.6)
10–15 years	475	358,75.4% (71.6–79.4)		214.8(194.5–237.2)
15–20 years	592	468,79.1% (75.7–82.4)		271.6(247.1–298.6)
20–30 years	630	522,82.9% (79.7–85.7)		274.8(253.3–298)
30–40 years	321	292,91.0% (87.9–94.1)		287.1(261.1–315.6)
40–60 years	617	550,89.1% (86.5–91.4)		296.5(278.3–315.8)
Gender
Male	2289	1769,77.3% (75.6–79.0)	P=0.039	235.5 (224.1–247.5)	P=0.023
Female	2636	2101,79.7% (78.0–81.3)		255.3 (244.0–267.1)
Number of vaccine doses
Zero	630	179, 28.4% (24.9–32.1)	P<0.001	52.4(47.2–58.1)	P<0.001
One	2306	2007, 87.0% (85.6–88.4)		336.5(323.1–350.5)
Two	155	136, 87.7% (82.0–92.9)		345.1(290.8–409.7)
Unknown	1834	1548, 84.4% (82.7–86.0)		274.2(262.1–286.8)
Total	4925	3870, 78.6% (77.4–79.8)		245.8(237.3–255.1)

Abbreviations: CI, confidence interval; GMC, geometric mean concentration.

Figure 1. Age specific mumps seroprevalence in 2009 and 2018. Error bars represent 95% CIs.

Figure 2. GMCs by age group in 2009 and 2018. Age specific geometric mean mumps antibody concentrations (GMCs) in 2009 (blue line) and 2018 (red line). Error bars represent 95% CI.

Table 2. Reported cases and incidence in 2005–2019, Fujian province, China.

Year	Incidence (1/ 100,000)	Number of cases	Cases (N, %)
			Clinically diagnosed	Laboratory confirmed	Male	Female
2005	25.5	9000	8930(99.2)	70(0.8)	5945(66.1)	3055(33.9)
2006	14.5	5193	5133(98.8)	60(1.2)	3363(64.8)	1830(35.2)
2007	9.7	3520	3483(98.9)	37(1.1)	2294(65.2)	1226(34.8)
2008	13.7	4970	4915(98.9)	55(1.1)	3279(66.0)	1691(34.0)
2009	14.5	5263	5224(99.3)	39(0.7)	3410(64.8)	1853(35.2)
2010	23.7	8613	8547(99.2)	66(0.8)	5557(64.5)	3056(35.5)
2011	43.2	15,957	15,776(98.9)	181(1.1)	10,154(63.6)	5803(36.4)
2012	37.3	13,981	13,849(99.1)	132(0.9)	9033(64.6)	4948(35.4)
2013	13.8	5571	5521(99.1)	50(0.9)	3514(63.1)	2057(36.9)
2014	9.4	3763	3701(98.4)	62(1.6)	2367(62.9)	1396(37.1)
2015	8.0	3048	2998(98.4)	50(1.6)	1947(63.9)	1101(36.1)
2016	7.7	2945	2889(98.1)	56(1.9)	1827(62.0)	1118(38.0)
2017	7.5	2897	2843(98.1)	54(1.9)	1835(63.3)	1062(36.7)
2018	7.8	3030	2968(98.0)	62(2.0)	1880(62.0)	1150(38.0)
2019	8.0	3171	3113(98.2)	58(1.8)	1975(62.3)	1196(37.7)

Figure 3. Epidemiological characteristics of mumps in Fujian province, 2005–2019.